Guikai George Wu

Amberstone Biosciences, Inc. is a company that aims to eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. The company is based in Laguna Hills, CA. The company's team of scientists and engineers strives to discover and develop transformative immunotherapeutics, pioneering a new wave of therapeutic breakthroughs. The company is developing first-in-class tumor microenvironment activated therapeutic (T-MATE). The company was founded in 2018 by Guikai George Wu. Guikai George Wu has been the CEO since 2018.